; and (B) by striking $18,336,340 and inserting $25,000,000 ; and (2) in paragraph (2)— (A) in subparagraph (A)— (i) by striking 25 percent and inserting 20 percent ; and (ii) by inserting before the semicolon at the end the following: and fees under subsection (a)(4) (relating to generic investigational new animal drug files) ; (B) in subparagraph (B), by striking 37.5 percent and inserting 40 percent ; and (C) in subparagraph (C), by striking 37.5 percent and inserting 40 percent . (c) Annual fee setting; adjustments (1) Annual fee setting Section 741(c)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21(c)(1) ) is amended to read as follows: (1) Annual fee setting The Secretary shall establish, not later than 60 days before the start of each fiscal year beginning after September 30, 2023, for that fiscal year— (A) abbreviated application fees that are based on the revenue amounts established under subsection (b), the adjustments provided under this subsection, and the amount of fees anticipated to be collected under subsection (a)(4) during that fiscal year; (B) generic new animal drug sponsor fees, and generic new animal drug product fees, based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection; and (C) a generic investigational new animal drug file fee of $50,000 for each request or submission described in subsection (a)(4)(A). . (2) Inflation adjustment Section 741(c)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21(c)(2) ) is amended— (A) in subparagraph (A)— (i) in the matter preceding clause (i), by striking 2020 and inserting 2025 ; and (ii) in clause (iii), by striking Baltimore and inserting Arlington-Alexandria ; and (B) in subparagraph (B), by striking 2020 and inserting 2025 . (3) Workload adjustment Section 741(c)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–21(c)(3) ) is amended— (A) in subparagraph (A)— (i) in the matter preceding clause (i), by striking 2020 and inserting 2025